Kie Kyon Huang

Title: Kie Kyon Huang: Innovator in Cancer Therapy Prediction

Introduction

Kie Kyon Huang is a notable inventor based in Singapore, recognized for his contributions to cancer therapy. His innovative work focuses on improving patient outcomes through advanced predictive methods in immune checkpoint inhibition therapy. With a single patent to his name, Huang's research has the potential to significantly impact cancer treatment protocols.

Latest Patents

Huang's patent, titled "Method of predicting for benefit from immune checkpoint inhibition therapy," outlines a novel approach to identifying patients who may benefit from this type of therapy. The method involves measuring the expression levels of specific markers in cancerous biological samples. By identifying differentially expressed alternative promoters and calculating an alternative promoter usage score, the method allows for the determination of whether a patient is likely to benefit from immune checkpoint inhibition therapy. Additionally, the invention introduces a biomarker that can help exclude patients from receiving this therapy if they are unlikely to benefit.

Career Highlights

Throughout his career, Kie Kyon Huang has worked with esteemed organizations such as the Agency for Science, Technology and Research and the National University Hospital (Singapore) Pte. Ltd. His experience in these institutions has provided him with a solid foundation in research and development, particularly in the field of oncology.

Collaborations

Huang has collaborated with notable colleagues, including Patrick Tan and Raghav Sundar. These partnerships have likely contributed to the depth and breadth of his research, fostering an environment of innovation and discovery.

Conclusion

Kie Kyon Huang's work in developing predictive methods for cancer therapy represents a significant advancement in the field of oncology. His innovative approach has the potential to enhance patient care and treatment outcomes, marking him as a key figure in medical research.